Celcuity CEO to present at Wells Fargo healthcare conference fireside chatPUBT·1 day ago, 12:32 PMCELC+4.59%
Celcuity submits FDA sNDA for REVTORPYK in PIK3CA-mutant advanced breast cancerPUBT·Aug 26 at 12:31 PMCELC+4.59%
Celcuity (CELC) Losses Widen As Investors Ask If The Bull Case Still Supports ValuationSimplywall·Aug 23 at 07:34 PMCELC+4.59%
Celcuity (CELC) Q2 2026 Earnings Call: REVTORPYK Launch Set for Late Q3TradingKey·Aug 14 at 08:04 PMCELC+4.59%
Unchanged $165 Target as Gedatolisib’s Strong Clinical Profile and FDA Approval Support Buy RatingTip Ranks·Aug 14 at 05:15 PMCELC+4.59%
Celcuity Inc. Stock 12‑Month Price Target Cut to $160.64, Implies 85% UpsideTradingView·Aug 14 at 12:20 PMCELC+4.59%
Celcuity Reports Q2 2026 Results: Full Earnings Call Transcriptbenzinga_article·Aug 13 at 09:24 PMCELC+4.59%
US Multi-Sector Scan: Earnings Divergence and Key Movers in FocusGlobal Report·Aug 11 at 10:13 AMCELC+4.59%EM0.00%
Mid-Cap Tech and Biotech See Divergent Moves Amid AI Pivots and Strategic M&AGlobal Report·Aug 8 at 09:20 AMNIVF-9.02%STRF+0.17%
The Market's Junk Drawer: From Obesity Drug Chasers to Sinking BiotechsGlobal Report·Aug 6 at 09:15 AMGOVX-8.77%ADPT+1.31%
CELC Investors Have Opportunity to Join Celcuity Inc. Fraud Investigation with SBS LawPR Newswire·Aug 3 at 05:08 AMCELC+4.59%
